引用本文:姚 祥,蒋 静.恩替卡韦对乙肝肝硬化代偿期患者HBV-DNA水平及肝功能的影响[J].中国临床新医学,2018,11(11):1133-1135.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 52次   下载 31 本文二维码信息
码上扫一扫!
分享到: 微信 更多
恩替卡韦对乙肝肝硬化代偿期患者HBV-DNA水平及肝功能的影响
姚 祥,蒋 静
476600 河南,永城市人民医院感染科
摘要:
[摘要] 目的 探讨恩替卡韦对乙肝肝硬化代偿期患者乙型肝炎病毒DNA(HBV-DNA)水平及肝功能的影响。方法 选取2014-08~2016-10治疗的乙肝肝硬化代偿期患者62例为研究对象,按照随机数字表法分为两组,各31例。对照组给予阿德福韦酯片口服治疗,观察组服用恩替卡韦治疗。均连续治疗6个月。比较两组患者治疗前后HBV-DNA水平及肝功能情况。结果 对照组治疗后HBV-DNA水平比观察组高,差异有统计学意义(P<0.05);观察组治疗后HBV-DNA水平下降幅度大于对照组下降幅度,差异有统计学意义(P<0.05)。观察组治疗后谷草转氨酶、谷丙转氨酶、总胆红素水平下降幅度大于对照组下降幅度,差异有统计学意义(P<0.05)。结论 恩替卡韦治疗能有效降低乙肝肝硬化代偿期患者HBV-DNA水平,改善患者肝功能状况,提高临床治疗效果。
关键词:  恩替卡韦  乙肝肝硬化代偿期  乙型肝炎病毒DNA水平  肝功能
DOI:10.3969/j.issn.1674-3806.2018.11.18
分类号:R 512.6+2
基金项目:
Effects of entecavir on HBV-DNA level and liver function in patients with decompensated hepatitis B liver cirrhosis
YAO Xiang, JIANG Jing
Department of Infectious Diseases, the People′s Hospital of Yongcheng City, Henan 476600, China
Abstract:
[Abstract] Objective To investigate the effects of entecavir on hepatitis B virus DNA(HBV-DNA) and liver function in patients with decompensated hepatitis B liver cirrhosis. Methods Sixty-two patients with decompensated hepatitis B liver cirrhosis from August 2014 to October 2016 were selected as the study subjects, and were divided into two groups according to the random number table method, with 31 cases in each group. The control group was treated with adefovir dipivoxil orally and the observation group was treated with entecavir for 6 months. HBV-DNA levels and liver function were compared between the two groups before and after treatment. Results The level of HBV-DNA in the control group was significantly higher than that in the observation group(P<0.05). The decrease of HBV-DNA level in the observation group was significantly sharper than that in the control group(P<0.05). After treatment, the decreases of aspartate aminotransferase, glutamic-pyruvic transaminase and total bilirubin in the observation group were significantly sharper than those in the control group(P<0.05). Conclusion  Entecavir can effectively reduce HBV-DNA levels in patients with decompensated hepatitis B liver cirrhosis, and improve their liver function and clinical effects.
Key words:  Entecavir  Decompensated hepatitis B liver cirrhosis  HBV-DNA level  Liver function